Product image of Linagliptina Medochemie (Linagliptin) supplied by GNH India

Linagliptina Medochemie

Active Ingredient:
Linagliptin
Origin:
EU

Linagliptina Medochemie (Linagliptin)

Linagliptin, the active ingredient in Linagliptina Medochemie, is a DPP-4 inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of type 2 diabetes mellitus in adults and helps improve glycaemic control.
GNH India supplies Linagliptina Medochemie as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Medochemie Ltd.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptin is a DPP‑4 inhibitor used to manage glucose levels in type 2 diabetes mellitus.

  • Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial blood glucose when used alone.
  • Type 2 diabetes mellitus (combination therapy): enhances glycaemic control when added to metformin, sulfonylureas or insulin.
  • Type 2 diabetes mellitus with renal impairment: provides effective glucose lowering without dose adjustment in patients with reduced kidney function.

How It Works

  • Linagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, preventing the breakdown of the incretin hormones GLP‑1 and GIP. Elevated incretin levels increase glucose‑dependent insulin secretion and suppress glucagon release, thereby improving post‑prandial and overall glycaemic control in patients with type 2 diabetes.

Side Effects

Common Side Effects

  • Nasopharyngitis: mild upper respiratory infection symptoms.
  • Headache: transient mild to moderate pain.
  • Upper respiratory tract infection: cough, sore throat.
  • Dizziness: occasional light‑headedness.
  • Gastrointestinal discomfort: nausea or abdominal pain.
  • Back pain: occasional musculoskeletal ache.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe allergic reactions: angioedema, Stevens‑Johnson syndrome, or anaphylaxis.
  • Hepatic injury: elevated liver enzymes or jaundice.
  • Severe hypoglycaemia: especially when combined with insulin or sulfonylureas.
  • Bullous pemphigoid: rare autoimmune skin disorder.

Precautions & Warnings

Linagliptin should be used with clinical monitoring in several situations.

  • Renal impairment: no dose adjustment required, but monitor renal function regularly.
  • Hepatic impairment: use with caution and assess liver enzymes periodically.
  • Risk of hypoglycaemia: heightened when combined with insulin or sulfonylureas; educate patients on recognising low blood sugar.
  • Pancreatitis: discontinue if persistent severe abdominal pain occurs.
  • Pregnancy and lactation: safety not established; avoid unless benefits outweigh potential risks.
  • Store at ambient temperature: keep below 25 °C, protect from moisture and light, retain in original packaging.

Avoid Interactions

Linagliptin may interact with several medicines that affect glucose levels or drug metabolism.

Major Interactions (Avoid)

  • Insulin: concurrent use can cause significant hypoglycaemia.
  • Sulfonylureas (e.g., glimepiride): increased risk of low blood glucose.
  • Strong CYP3A4 inducers (e.g., rifampin): may reduce linagliptin exposure.

Moderate Interactions (Monitor Closely):\n- ACE inhibitors or ARBs: monitor for angioedema, especially in patients with a history.

  • Diuretics: assess renal function and electrolytes.
  • Warfarin: check INR more frequently.
  • Digoxin: observe for any change in serum levels.

Frequently Asked Questions

Linagliptina Medochemie contains linagliptin, a DPP‑4 inhibitor indicated for improving glycaemic control in adults with type 2 diabetes mellitus, either as a single therapy or in combination with other antidiabetic agents.

Linagliptin blocks the DPP‑4 enzyme, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, the drug enhances glucose‑dependent insulin release and reduces glucagon secretion, leading to lower blood glucose levels.

The prescribed dose is determined by the treating physician based on the patient’s clinical condition. In many regions the standard starting dose is 5 mg taken once daily, but the exact regimen should follow the prescriber’s instructions.

Safety of linagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified health professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin is unique among DPP‑4 inhibitors because it is eliminated primarily via the entero‑hepatic route, allowing use without dose adjustment in renal impairment. Efficacy and safety profiles are broadly comparable to other agents such as sitagliptin or saxagliptin, but individual patient factors guide selection.

Store the tablets at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep out of reach of children and do not use if the packaging is damaged.

The medication is taken orally as a whole tablet, usually once daily, with or without food. Swallow the tablet with a glass of water and do not split, crush or chew unless specifically instructed by a healthcare provider.

Serious adverse events include pancreatitis, severe allergic reactions such as angioedema or Stevens‑Johnson syndrome, and significant hypoglycaemia when used together with insulin or sulfonylureas. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or signs of low blood sugar.

Linagliptin is contraindicated in individuals with a known hypersensitivity to linagliptin or any component of the formulation. It is also not recommended for patients with type 1 diabetes, diabetic ketoacidosis, or severe hepatic impairment without careful medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT